期刊
EMBO JOURNAL
卷 38, 期 23, 页码 -出版社
WILEY
DOI: 10.15252/embj.2019102345
关键词
axonal dystrophies; BACE1; tau deletion; two-photon in vivo microscopy; beta-amyloid plaque
资金
- Munich Cluster for Systems Neurology SyNergy [EXC1010]
- ITN Extrabrain [606950]
- ITN SynDegen [721802]
- Centers of Excellence in Neurodegeneration (COEN)
In Alzheimer's disease, BACE1 protease initiates the amyloidogenic processing of amyloid precursor protein (APP) that eventually results in synthesis of beta-amyloid (A beta) peptide. A beta deposition in turn causes accumulation of BACE1 in plaque-associated dystrophic neurites, thereby potentiating progressive A beta deposition once initiated. Since systemic pharmacological BACE inhibition causes adverse effects in humans, it is important to identify strategies that specifically normalize overt BACE1 activity around plaques. The microtubule-associated protein tau regulates axonal transport of proteins, and tau deletion rescues A beta-induced transport deficits in vitro. In the current study, long-term in vivo two-photon microscopy and immunohistochemistry were performed in tau-deficient APPPS1 mice. Tau deletion reduced plaque-associated axonal pathology and BACE1 accumulation without affecting physiological BACE1 expression distant from plaques. Thereby, tau deletion effectively decelerated formation of new plaques and reduced plaque compactness. The data revealed that tau reinforces A beta deposition, presumably by contributing to accumulation of BACE1 in plaque-associated dystrophies. Targeting tau-dependent mechanisms could become a suitable strategy to specifically reduce overt BACE1 activity around plaques, thereby avoiding adverse effects of systemic BACE inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据